Senkal M, Mumme A, Eickhoff U, Geier B, Späth G, Wulfert D, Joosten U, Frei A, Kemen M
Department of Surgery, Ruhr-University Bochum, St. Josef Hospital, Germany.
Crit Care Med. 1997 Sep;25(9):1489-96. doi: 10.1097/00003246-199709000-00015.
To determine if early postoperative feeding of patients with upper gastrointestinal malignancy, using an enteral diet supplemented with arginine, dietary nucleotides, and omega-3 fatty acids (IMPACT, Sandoz Nutrition, Bern, Switzerland) results in an improved clinical outcome, i.e., reduced infectious and wound complications and decreased treatment costs when compared with an isocaloric, isonitrogenous control diet.
A prospective, randomized, placebo-controlled, double-blind, multicenter trial of the clinical outcome and a retrospective cost-comparison analysis.
Surgical intensive care units in three different German university hospitals.
Of 164 patients enrolled in the study, 154 patients were eligible for analysis. They were admitted to the intensive care unit after upper gastrointestinal surgery for cancer and they received an enteral diet via needle catheter jejunostomy. Infectious complications were defined as sepsis or systemic inflammatory response syndrome, pneumonia, urinary tract infection, central venous catheter sepsis, wound infection, and anastomotic leakage. The complication events were prospectively divided into two groups: early (postoperative days 1 to 5) and late (after the fifth postoperative day) postoperative complications. The treatment costs of each complication were analyzed and compared in both groups.
Patients were randomized to receive either the immunonutritional diet (n = 77) or an isocaloric and isonitrogenous placebo diet (n = 77). Enteral feeding was initiated 12 to 24 hrs after surgery, starting with 20 mL/hr and advanced to a target volume of 80 mL/hr by postoperative day 5.
Clinical examination and adverse gastrointestinal symptoms were recorded on a daily basis. Both groups tolerated early enteral feeding well, and the rate of tube feeding-related complications was low. Postoperative complications occurred in 17 patients in the immunonutrition group vs. 24 patients in the control group (NS). Further, in the early phase (postoperative day 1 to 5), complications occurred to a similar extent in both groups (12 patients in the immunonutritional group vs. 11 patients in the control group). However, in the late phase (after postoperative day 5), considerably fewer patients in the experimental diet group experienced complications compared with the control group (5 vs. 13, p < .05). In addition, the frequency rate of complicating events were recorded in each group. In the experimental diet group, a total of 22 complicating events were recorded vs. a total of 32 events in the placebo diet group (NS). However, the occurrence of late complicating events, i.e., complicating events after the fifth postoperative day, was significantly reduced in the immunonutrition group when compared with the control group (8 vs. 17 events, p < .05). The total costs for the treatment of the complications were 83,563 German marks in the experimental diet group vs. 122,430 German marks in the control group, resulting in a cost-reduction of 38,867 German marks. (At the end of December 1995, the conversion rate from German marks to U.S. dollars was 1.4365 German marks to $1.00.)
Early enteral feeding with an arginine, dietary nucleotides, and omega-3 fatty acids supplemented diet, as well as an isonitrogenous, isocaloric control diet (placebo) were well tolerated in patients who underwent upper gastrointestinal surgery. In patients who received the supplemented diet, a significant reduction in the frequency rate of late postoperative infectious and wound complications was observed. Thereby, the treatment costs were substantially reduced in the immunonutrition group as compared with the control group.
确定对上消化道恶性肿瘤患者术后早期给予补充精氨酸、膳食核苷酸和ω-3脂肪酸的肠内营养制剂(IMPACT,山德士营养公司,瑞士伯尔尼),与等热量、等氮的对照饮食相比,是否能改善临床结局,即减少感染和伤口并发症,并降低治疗费用。
一项关于临床结局的前瞻性、随机、安慰剂对照、双盲、多中心试验以及回顾性成本比较分析。
德国三家不同大学医院的外科重症监护病房。
164例纳入研究的患者中,154例符合分析条件。他们因癌症接受上消化道手术后入住重症监护病房,并通过针导管空肠造口术接受肠内营养。感染性并发症定义为败血症或全身炎症反应综合征、肺炎、尿路感染、中心静脉导管败血症、伤口感染和吻合口漏。并发症事件前瞻性地分为两组:早期(术后第1至5天)和晚期(术后第5天之后)术后并发症。对两组中每种并发症的治疗费用进行分析和比较。
患者被随机分为接受免疫营养饮食组(n = 77)或等热量、等氮的安慰剂饮食组(n = 77)。术后12至24小时开始肠内喂养,起始速度为20毫升/小时,到术后第5天增至目标量80毫升/小时。
每天记录临床检查和不良胃肠道症状。两组对早期肠内喂养耐受性良好,管饲相关并发症发生率低。免疫营养组17例患者发生术后并发症,对照组为24例患者(无统计学差异)。此外,在早期(术后第1至5天),两组并发症发生率相似(免疫营养组12例患者,对照组11例患者)。然而,在晚期(术后第5天之后),与对照组相比,试验饮食组发生并发症的患者明显减少(5例对13例,p <.05)。另外,记录了每组并发症事件的发生率。试验饮食组共记录22例并发症事件,安慰剂饮食组共32例事件(无统计学差异)。然而,与对照组相比,免疫营养组术后晚期并发症事件(即术后第5天之后的并发症事件)的发生率显著降低(8例对17例,p <.05)。试验饮食组并发症治疗总费用为83,563德国马克,对照组为122,430德国马克,费用降低了38,867德国马克。(1995年12月底,德国马克与美元的兑换率为1.4365德国马克兑换1美元。)
对上消化道手术患者,早期给予补充精氨酸、膳食核苷酸和ω-3脂肪酸的饮食以及等氮、等热量的对照饮食(安慰剂)耐受性良好。接受补充饮食的患者,术后晚期感染和伤口并发症的发生率显著降低。因此,与对照组相比,免疫营养组的治疗费用大幅降低。